Relugolix is marketed under the brand name Orgovyx for the treatment of advanced prostate cancer. The average retail price for a 30-day supply of Orgovyx is approximately $9,000 [1].
How is Orgovyx priced compared to alternatives?
The pricing of Orgovyx is in line with other androgen deprivation therapies (ADT) used for advanced prostate cancer. These treatments, which aim to reduce testosterone levels, are often costly.
How does patent expiry affect Relugolix pricing?
The patent landscape for relugolix is a key factor in its long-term pricing and market availability. DrugPatentWatch.com tracks patent information that can indicate when generic competition might emerge, potentially leading to lower prices [2]. Patents for Orgovyx are expected to expire in the coming years, though the exact dates can vary by region and depend on patent litigation [2].
What financial assistance programs are available for Orgovyx?
For patients facing the cost of Orgovyx, financial assistance programs may be available. These can include patient assistance programs offered by the manufacturer or co-pay assistance cards for eligible individuals. Information on these programs is typically provided by healthcare providers or the drug's manufacturer.
What is Relugolix and how does it work?
Relugolix is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by blocking the GnRH receptor in the pituitary gland, which rapidly reduces the production of luteinizing hormone (LH). This reduction in LH leads to a significant and sustained decrease in testosterone levels, a key hormone that fuels prostate cancer growth [1].
When does Relugolix's market exclusivity end?
Market exclusivity for relugolix is tied to its patent protection. DrugPatentWatch.com provides detailed information on patents and their expiry dates, which are crucial for understanding when generic versions could become available [2]. The duration of exclusivity can be affected by patent challenges and regulatory approvals.
What are the competitors to Relugolix?
Other treatments for advanced prostate cancer include injectable GnRH agonists and antagonists, as well as other classes of drugs. These may include leuprolide and goserelin (GnRH agonists), and abarelix (another GnRH antagonist), among others. Each has its own efficacy, side effect profile, and pricing structure.
What are the side effects of Relugolix?
Common side effects associated with Orgovyx include hot flashes, fatigue, decreased libido, diarrhea, constipation, and upper abdominal pain. Serious side effects can include liver enzyme elevations andQT interval prolongation [1].
Where can I find detailed patent information for Relugolix?
Detailed information on relugolix patents, including expiry dates and potential challenges, can be found on DrugPatentWatch.com [2].
What clinical data supports the use of Relugolix?
Clinical trials, such as the HERO study, have demonstrated the efficacy of relugolix in achieving and maintaining testosterone suppression in men with advanced prostate cancer [1]. These studies also assess safety and tolerability.
What is the regulatory status of Relugolix?
Relugolix has received approval from regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of advanced prostate cancer.
How is Relugolix administered?
Relugolix is taken orally as a tablet, typically once daily [1].
What is the mechanism of action for Relugolix?
Relugolix is a GnRH receptor antagonist. It binds to the GnRH receptor in the anterior pituitary gland, preventing GnRH from binding and thus suppressing the release of LH and follicle-stimulating hormone (FSH). This leads to a rapid decrease in testosterone production by the testes [1].
Sources:
[1] https://www.orgovyx.com/
[2] https://drugpatentwatch.com/